Traders should monitor upcoming clinical data readouts in mid-2026 as key catalysts; the extended cash runway reduces near-term dilution risk, but continued losses suggest future financing may be needed if trials require larger investments.
Price Chart
Executive Summary
Context Therapeutics reported its 2025 financial results, showing increased R&D spending and a wider net loss, while cash reserves declined to $66.0 million. The company provided updates on its clinical pipeline, including upcoming interim data readouts for CTIM-76 in June 2026 and CT-95 in September 2026, and plans to initiate the CT-202 trial in Q3 2026.
Key Financial Metrics
Key Facts
- Net loss increased to $36.1 million in 2025 from $26.7 million in 2024
- R&D expenses rose to $31.9 million in 2025 from $22.7 million in 2024
- Cash and cash equivalents decreased to $66.0 million as of December 31, 2025, from $94.4 million a year earlier
- Company expects cash runway into mid-2027
- Interim Phase 1a data for CTIM-76 expected in June 2026; CT-95 interim data expected in September 2026
- First patient dosing for CT-202 trial expected in Q3 2026
Financial Impact
Net loss increased by $9.4 million year-over-year; cash burn increased due to higher R&D investment
Risk Factors
- Increasing net losses and cash burn could pressure future financing needs
- Clinical trial delays or adverse data could negatively impact stock performance
- No revenue-generating products; company remains pre-revenue with high dependence on trial outcomes
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3260846 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 15, 2026 19w ago | 8-K | $0.6791 $0.6299 | ▼ −7.24% | ▼ −5.86% | $0.2347 (−65.44%) |
Jun 15, 2026 19w ago | Press Release | $0.6791 $0.6299 | ▼ −7.24% | ▼ −5.86% | $0.2347 (−65.44%) |
May 18, 2026 23w ago | PRESS-RELEASE / 8-K | $2.15 $2.63 | ▲ +22.33% | ▲ +20.71% | $0.2347 (−89.08%) |
May 6, 2026 24w ago | Press Release | $2.33 $2.36 | ▲ +1.29% | ▼ −0.22% | $0.2347 (−89.93%) |
May 1, 2026 25w ago | 8-K | $2.30 $2.39 | ▲ +3.91% | ▲ +0.98% | $0.2347 (−89.80%) |
Apr 2, 2026 29w ago | 8-K | $2.72 $2.49 | ▼ −8.46% | ▼ −12.07% | $0.2347 (−91.37%) |
Mar 23, 2026 31w ago | Press Release | $3.18 $2.62 | ▼ −17.61% | ▼ −17.19% | $0.2347 (−92.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers